Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec;101(Pt A):108200.
doi: 10.1016/j.intimp.2021.108200. Epub 2021 Sep 28.

Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?

Simone Mornese Pinna  1 , Tommaso Lupia  2 , Silvia Scabini  1 , Davide Vita  1 , Ilaria De Benedetto  1 , Alberto Gaviraghi  1 , Irene Colasanto  3 , Alessandra Varese  3 , Francesco Cattel  3 , Francesco Giuseppe De Rosa  1 , Silvia Corcione  4
Affiliations
Review

Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?

Simone Mornese Pinna et al. Int Immunopharmacol. 2021 Dec.

Abstract

The world is facing up the most considerable vaccination effort in history to end the Coronavirus disease 2019 (COVID-19) pandemic. Several monoclonal antibodies (mAbs) direct against the Receptor binding domain of the S protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) received an Emergency Use Authorization for outpatient management of mild to moderate manifestation from COVID-19. MAbs could prevent the transmission SARS-CoV-2 infection and protect individuals from progression to severe disease. Under the pressure of different treatment strategies, SARS-CoV-2 has been demonstrated to select for different sets of mutations named "variants" that could impair the effectiveness of mAbs by modifying target epitopes. We provide an overview of both completed and unpublished, or ongoing clinical trials of mAbs used and review state of art in order to describe clinical options, possible indications, and the place in therapy for these agents in the treatment of COVID-19 with a particular focus on anti-spike agents. Then, we reassume the current evidence on mutations of the SARS-CoV-2 that might confer resistance to neutralization by multiple mAbs.

Keywords: COVID-19; Monoclonal antibodies; Pneumonia; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Advantages and Weaknesses of Casirivimab and Imdevimab.
Fig. 2
Fig. 2
Advantages and Weaknesses of Bamlanivimab and Etesevimab.
See this image and copyright information in PMC

References

    1. Azer S.A. COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics. New Microbes New Infect. 2020;37 doi: 10.1016/j.nmni.2020.100738. - DOI - PMC - PubMed
    1. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2021 Jul 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 32150360. - PubMed
    1. Mehta R.M., Bansal S., Bysani S., Kalpakam H. A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis. Int J Infect Dis. 2021;106:71–77. doi: 10.1016/j.ijid.2021.02.092. - DOI - PMC - PubMed
    1. Mongardon N, Piagnerelli M, Grimaldi D, Perrot B, Lascarrou JB; COVADIS study group investigators. Impact of late administration of corticosteroids in COVID-19 ARDS. Intensive Care Med. 2021 Jan;47(1):110-112. doi: 10.1007/s00134-020-06311-z. Epub 2020 Nov 6. PMID: 33156381; PMCID: PMC7645397. - PMC - PubMed
    1. Liu J., Zhang S., Dong X., Li Z., Xu Q., Feng H., Cai J., Huang S., Guo J., Zhang L., Chen Y., Zhu W., Du H., Liu Y., Wang T., Chen L., Wen Z., Annane D., Qu J., Chen D. Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome. J Clin Invest. 2020 Dec 1;130(12):6417–6428. - PMC - PubMed

MeSH terms